← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Biocryst Pharmaceuticals, Inc.
Birmingham, AL
$48,356,557
Total funding
4
Grants
Funding over time
peak $14.9M · FY2013–23$20M$15M$10M$5M$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$48,356,557 · 4
By mechanism
N01$47,658,567 · 2
R43$697,990 · 2
Investigators at Biocryst Pharmaceuticals, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Development of Medical Countermeasures for Biodefense and Emerging Diseases$14,916,023
N01 · FY2014 · AI
Development of Medical Countermeasures for Biodefense and Emerging Diseases$9,601,843
N01 · FY2016 · AI
DEVELOPMENT OF THERAPEUTIC PRODUCTS FOR COVID-19$6,326,480
N01 · FY2020 · AI
Development of Medical Countermeasures for Biodefense and Emerging Diseases$4,996,104
N01 · FY2013 · AI
Development of Medical Countermeasures for Biodefense and Emerging Diseases$3,557,707
N01 · FY2018 · AI
Development of Medical Countermeasures for Biodefense and Emerging Diseases$3,539,289
N01 · FY2015 · AI
Development of Medical Countermeasures for COVID-19$2,896,627
N01 · FY2020 · AI
Development of Medical Countermeasures for COVID-19$1,383,666
N01 · FY2021 · AI
Development of Medical Countermeasures for COVID-19$440,828
N01 · FY2023 · AI
Optimizing Hepatitis C virus NS5B Polymerase Inhibitors$300,000
R43 · FY2003 · AI
Optimizing Hepatitis C virus NS5B Polymerase Inhibitors$300,000
R43 · FY2004 · AI
EFFECTS OF TF/FVIIa INHIBITION IN CRP TRANSGENIC MICE$97,990
R43 · FY2004 · HL